Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + R-CHP vs R-CHOP in Previously Untreated DLBCL
NCT03274492Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2017
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 22
01
Overview
A Phase 3 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Started Nov 2017; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03274492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274492.